Cohort of 198 coronary artery bypass grafting patients monitored for 1 year with insertable cardiac devices found high incidence of new-onset atrial fibrillation but minimal late burden.
Lurbinectedin (Zepzelca) in combination with atezolizumab (Tecentriq) or atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) was approved for maintenance treatment of adults with extensive-stage s...
Federal shutdown suspends some health services, limits National Institutes of Health research, and raises questions about Affordable Care Act subsidies, Medicaid, and public health programs.